[Skip to Navigation]
Sign In
Correction
September 2018

Error in Figure

JAMA Neurol. 2018;75(9):1156. doi:10.1001/jamaneurol.2018.2840

In the Original Investigation titled “Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial,”1 published online May 29, 2018, there was an error in Figure 1. In the bottom middle box, reflecting the number of patients who completed double-blind treatment in the galcanezumab 240-mg dose group, the percentage should read 82.5%. This article was corrected online.

References
1.
Stauffer  VL, Dodick  DW, Zhang  Q, Carter  JN, Ailani  J, Conley  RR.  Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial  [published online May 29, 2018].  JAMA Neurol. doi:10.1001/jamaneurol.2018.1212PubMedGoogle Scholar
×